ASLAN Pharmaceuticals Pte Ltd, an Asia-enabled pharmaceutical company that develops novel medicines for global markets, announces the completion of a Series A financing led by BV Healthcare II. This provides ASLAN with US$12 million to develop its first in-licensed compounds. Other investors include Sagamore Bioventures and entrepreneurs from China, Hong Kong and the United States.

Click here for the full press release.